Tumor-Associated CD204-Positive Macrophage Is a Prognostic Marker in Clinical Stage I Lung Adenocarcinoma
Table 2
CD204+ macrophage density in clinical stage I lung adenocarcinoma and DFS.
Univariate analysis
Multivariate analysis
HR (95% CI)
p value
HR (95% CI)
p value
CD204 (high versus low)
20.91 (4.87–89.82)
<0.001
17.10 (3.37–86.68)
0.001
Gender (male versus female)
2.19 (0.91–5.29)
0.081
3.23 (0.95–10.94)
0.060
Age (≥70 versus <70 years)
1.23 (0.52–2.90)
0.633
0.60 (0.23–1.58)
0.304
Side (right versus left)
1.07 (0.44–2.58)
0.881
1.39 (0.54–3.55)
0.495
Smoking (yes versus no)
2.94 (1.14–7.57)
0.260
0.42 (0.11–1.53)
0.187
Histology (LPD versus non-LPD)
1.97 (1.47–2.64)
<0.01
2.86 (1.65–4.95)
<0.001
Tumor stage (T1a versus T1b)
3.22 (1.33–7.77)
0.009
1.92 (0.72–5.13)
0.196
Nodal involvement (yes versus no)
21.7 (9.07–51.9)
<0.001
5.64 (1.64–19.40)
0.006
LVI (yes versus no)
21.34 (7.15–63.66)
<0.001
2.48 (0.58–10.61)
0.221
The multivariate Cox regression models initially included CD204 status, gender, age, tumor side, history of smoking, histologic subtype, tumor stage, nodal involvement, and lymphovascular invasion. Backward elimination was performed with a threshold of . DFS: disease-free survival; CI: confidence interval; HR: hazard ratio; LPD: lepidic; LVI: lymphovascular invasion.
